Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States by Burton, F. et al.
Use and perceived effectiveness of non-analgesic medical
therapies for chronic pancreatitis in the United States
F. Burton*,1, S. Alkaade*, D. Collins, V. Muddana, A. Slivka, R. E. Brand, A. Gelrud, P. A. Banks§, S. Sherman–,
M. A. Anderson**, J. Romagnuolo, C. Lawrence, J. Baillie, T. B. Gardner§§, M. D. Lewis––, S. T. Amann***,
J. G. Lieb II, M. O’Connell, E. D. Kennard, D. Yadav, D. C. Whitcomb & C. E. Forsmark for the North
American Pancreatic Study Group2
*St. Louis University, St. Louis, MO, USA.
University of Florida, Gainesville, FL, USA.
University of Pittsburgh, Pittsburgh, PA,
USA.
§Brigham and Women’s Hospital, Boston,
MA, USA.
–Indiana University Medical Center, India-
napolis, IN, USA.
**University of Michigan, Ann Arbor, MI,
USA.
Digestive Disease Center, Medical
University of South Carolina, Charleston,
SC, USA.




––Mayo Clinic, Jacksonville, FL, USA.
***North Mississippi Medical Center,
Tupelo, MS, USA.
University of Pennsylvania School of
Medicine, Philadelphia, PA, USA.
Epidemiology Data Center, University
of Pittsburgh, Pittsburgh, PA, USA.
Correspondence to:
Dr D. Yadav, Division of Gastroenter-
ology, Hepatology and Nutrition,
Department of Medicine, University of
Pittsburgh Medical Center, 200
Lothrop Street, M2, C-Wing,
Pittsburgh, PA 15213, USA.
E-mail: yadavd@upmc.edu
1Professor Frank Burton passed away
during the final review phase of this
manuscript.
2A full list of contributing investiga-
tors is in the Appendix.
Publication data
Submitted 19 August 2010
First decision 6 September 2010
Resubmitted 30 September 2010
Accepted 1 October 2010
EV Pub Online 29 October 2010
SUMMARY
Background
Effectiveness of medical therapies in chronic pancreatitis has been described
in small studies of selected patients.
Aim
To describe frequency and perceived effectiveness of non-analgesic medical
therapies in chronic pancreatitis patients evaluated at US referral centres.
Methods
Using data on 516 chronic pancreatitis patients enrolled prospectively in the
NAPS2 Study, we evaluated how often medical therapies [pancreatic enzyme
replacement therapy (PERT), vitamins ⁄ antioxidants (AO), octreotide, coeliac
plexus block (CPB)] were utilized and considered useful by physicians.
Results
Oral PERT was commonly used (70%), more frequently in the presence of
exocrine insufficiency (EI) (88% vs. 61%, P < 0.001) and pain (74% vs.
59%, P < 0.002). On multivariable analyses, predictors of PERT usage were
EI (OR 5.14, 95% CI 2.87–9.18), constant (OR 3.42, 95% CI 1.93–6.04) or
intermittent pain (OR 1.98, 95% CI 1.14–3.45). Efficacy of PERT was pre-
dicted only by EI (OR 2.16, 95% CI 1.36–3.42). AO were tried less often
(14%) and were more effective in idiopathic and obstructive vs. alcoholic
chronic pancreatitis (25% vs. 4%, P = 0.03). Other therapies were infre-
quently used (CPB – 5%, octreotide – 7%) with efficacy generally <50%.
Conclusions
Pancreatic enzyme replacement therapy is commonly utilized, but is consid-
ered useful in only subsets of chronic pancreatitis patients. Other medical
therapies are used infrequently and have limited efficacy.
Aliment Pharmacol Ther 2011; 33: 149–159
ª 2010 Blackwell Publishing Ltd 149
doi:10.1111/j.1365-2036.2010.04491.x
Alimentary Pharmacology and Therapeutics
INTRODUCTION
Chronic pancreatitis (CP) is a progressive inflammatory
syndrome with multiple aetiologies, multiple complica-
tions and highly variable outcome. Pancreatic injury and
inflammation lead to dysfunction and ⁄ or loss of acinar
cells, duct cells and islet cells. Loss of these cells results
in clinical disorders of maldigestion, reduced bicarbonate
secretion and diabetes mellitus respectively. The suscepti-
bility of these specialized cells of the pancreas to injury,
the inflammatory response and adaptation to recurrent
injury are also variable between individuals, with each of
these processes modified by genetic, epigenetic, environ-
mental and metabolic factors. The injured pancreas also
contains inflammatory cells, pancreatic stellate cells and
sensory nerves, which contribute to complications of
fibrosis and pain. The deposition of calcified stones and
ductal scarring or stricturing may impede the normal
flow of pancreatic juice, and the loss of sufficient diges-
tive enzymes leads to maldigestion of ingested nutrients
with the clinical sequelae of bloating, cramping, abdomi-
nal pain, weight loss and malnutrition.1, 2 The pancreatic
pain syndrome is also very complex, with symptoms
arising from multiple sources, including mechanical
(obstructive),3 vascular (ischaemic),4 inflammatory,5 neu-
ropathic6, 7 and possibly hyperstimulatory aetiologies.8
The medical treatment of symptomatic CP is difficult
to standardize because of the complexity of the disease,
the variability between patients and the changing charac-
teristics of disease with progression of fibrosis or devel-
opment of complications. Thus, a wide variety of
empirical treatments are often tried for maldigestion and
pain. The spectrum of analgesic requirements by CP
patients ranges from acetaminophen and NSAIDs to
powerful narcotic agents. Some patients with CP suffer
from complications of duct obstruction that can be suc-
cessfully treated with endoscopic therapy or surgery.3 In
addition, several non-analgesic, mechanism-targeting
approaches have been introduced to help alleviate or
reduce pain.
Pain from pancreatic hyperstimulation can theoreti-
cally be reduced at the duodenum by giving oral pancre-
atic enzyme replacement therapy (PERT) with meals to
short-circuit the stimulation feedback signals by increas-
ing protease activity in the duodenum and decreasing
CCK-releasing factor.9 A second approach is to block
pancreatic stimulation with an inhibitory hormone ana-
logue, octreotide, which activates the somatostatin recep-
tor.10–12 A third approach is to reduce acinar cell
oxidative stress and injury by the use of vitamins and ⁄ or
antioxidants (AO).13, 14 A fourth approach is to block
directly the stimulatory (vagal) and sensory nerves to the
pancreas with a coeliac plexus block (CPB). The use and
perceived usefulness of these targeted approaches in clin-
ical practice within the US remain unknown.
In the present study, we used the North American
Pancreatitis Study 2 (NAPS2) cohort to obtain a cross-
sectional assessment of the frequency and physician-per-
ceived effectiveness of PERT, AO, CPB and octreotide in
CP patients evaluated at pancreas referral centres in the
US. In addition, we evaluated differences in use and per-
ceived effectiveness based on the aetiology of CP and on
the presence or absence of exocrine insufficiency (EI)
and pain. We assessed the use and efficacy of CPB with
other medical therapies as CPB does not qualify as an
endoscopic or surgical treatment.
METHODS
North American Pancreatitis Study 2
The study population was identified from within the
NAPS2, a 20-centre, prospective, cross-sectional, observa-
tional cohort study from the US consisting of 1000 sub-
jects with pancreatitis (recurrent acute pancreatitis = 460;
CP = 540), and 695 controls conducted between 2000
and 2006.15 The methodology of NAPS2 has been
detailed previously.15 The entry criteria for CP included
definitive evidence on computed tomography scan
and ⁄ or endoscopic retrograde cholangiopancreatography
with the Cambridge class II or more (83%) or documen-
tation of CP using magnetic resonance cholangiopancrea-
tography, endoscopic ultrasound (EUS) or pancreatic
histology in other enrollees.16 Each study subject com-
pleted a detailed questionnaire on personal and family
history, risk factors, symptoms and quality of life, and an
additional questionnaire was completed by a physician-
investigator with expertise in pancreatic diseases. The
physician questionnaire contained questions relating to
clinical phenotype, working diagnosis, risk factors, diag-
nostic and therapeutic interventions.15
Physician questionnaire
The information on use and effectiveness of medical
therapies, presence of endocrine or EI and aetiology was
obtained from responses provided by the enrolling physi-
cian in the physician questionnaire. In the section on
therapies, the physician was asked, ‘Which therapies
were attempted, and which of these were helpful’, and
given specific categories for medical (including PERT,
AO, CPB and octreotide), endoscopic and surgical treat-
ments. If the treatment had been tried, the physician was
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asked to select between the following choices: unchanged,
worse, helpful or not sure. Information on timing of
treatment before study enrolment, dosage, duration and
the formulation of PERT (enteric-coated or non-enteric
coated) or AO therapy was not asked. A therapy was
classified as effective if the physician chose ‘helpful’ as a
response. Patients could be counted for more than one
treatment. From 540 patients in the NAPS2 cohort with
CP, we excluded 24 (4%) patients in whom the enrolling
physicians did not indicate a trial occurred with any of
the therapeutic modalities (medical, endoscopic or surgi-
cal). The final sample size for analysis for this study was
therefore 516 ⁄ 540 (96%) CP patients.
The enrolling physician indicated whether endocrine
or EI was present and the method used to establish the
diagnosis. We determined the aetiology of CP based on
physician’s response to the question on working diagno-
sis. Physicians chose one or more working diagnosis
from among the following choices: alcohol, idiopathic,
hereditary, cystic fibrosis, pancreas divisum, hyperlipida-
emia, hypercalcaemia, trauma and others. Space was pro-
vided in the questionnaire to fill in the details. As more
than one working diagnosis could be selected, we used a
hierarchical algorithm to assign patients sequentially into
aetiological groups. In summary, patients in whom ‘alco-
hol’ was checked exclusively for its presence or checked
with other diagnoses were assigned to the ‘alcohol’
group; among the remaining patients, those with heredi-
tary or cystic fibrosis diagnosis with or without another
diagnoses were assigned to the ‘genetic’ group; among
remaining patients, those with autoimmune pancreatitis
diagnosis with or without another diagnoses were
assigned to the ‘autoimmune’ group; among remaining
patients, those with an obstructive aetiology with or
without another diagnoses were assigned to the ‘obstruc-
tive’ group; among the remaining patients, those identi-
fied with a specific aetiology not included in any of the
previous group were assigned to ‘other aetiologies’ group;
all the remaining patients were then assigned to ‘idio-
pathic’ group.
Patient questionnaire
The information on demographics, and presence and
pattern of pain was obtained from responses to the
patient questionnaire. Patients were asked if they had
abdominal pain, and to choose the pattern and severity
of pain from a list consisting of five options.15, 17, 18
Patients could characterize their pain experience as: (A)
episodes of mild-to-moderate pain, usually controlled by
medication; (B) constant mild-to-moderate pain usually
controlled by medication; (C) usually pain-free with epi-
sodes of severe pain; (D) constant mild pain plus epi-
sodes of severe pain; and (E) constant severe pain that
does not change. We classified patients based on the pat-
tern of pain [intermittent (Group A or C) or chronic
(Groups B, D, E)] and the severity of pain [mild-to-mod-
erate (Group A or B) or severe (Groups C, D, E)].
Statistics
Descriptive analyses are presented as proportions for cat-
egorical data, and as mean  standard deviation for con-
tinuous data. Univariate analysis for categorical data was
performed using the Chi-squared or Fischer’s exact test
as applicable to evaluate the proportion of patients in
whom individual medical therapies were tried, and, if a
therapy was tried, the proportion in whom physicians
believed that it was effective. Univariate comparisons for
continuous variables were made using the Student’s
t-test.
Multivariable logistic regression models were used to
determine independent predictors for PERT use and effi-
cacy. Due to small sample sizes for subjects in whom
other medical therapies were tried (AO, CPB and octreo-
tide), only univariate analyses were performed for the
use and efficacy of these treatments. All variables show-
ing a P-value of <0.10 in the univariate analysis were
chosen for initial inclusion into the regression models,
except for age and gender, which were forced into the
models. A backwards selection technique was used to
determine significant independent predictors. For class
variables, all observations were entered if one value of
the class was significant. Data were examined for collin-
earity, but showed no significant interactions. Two-sided
P-values <0.05 were considered significant. Data analysis
was performed with R Project software (http://www.
r-project.org) and SAS system version 9.2 (SAS Software
Institute, Cary, NC, USA).
RESULTS
Demographics, aetiology and use of medical therapies
The demographics of the overall NAPS2 cohort have
been previously reported.15, 19 In 516 ⁄ 540 (96%) patients
with CP in the NAPS2 cohort, the enrolling physicians
indicated the utilization and effectiveness of at least one
of the therapeutic modalities (medical, endoscopic or
surgical). The sample size for this study therefore con-
sisted of 516 patients. The mean age of these 516
patients was 49.2  15.6 years, 52% were male and 85%
were Caucasian. Alcohol was considered a single or
Medical therapies in chronic pancreatitis
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contributing aetiology in 44% patients, idiopathic CP in
29%, obstructive causes in 9%, whereas the remaining
patients had other aetiologies. At least one of the four
medical therapies was tried in 383 ⁄ 516 (74%) patients.
In 283 (55%), only one medical therapy was utilized,
while two or more than two medical therapies were used
in 89 ⁄ 516 (17%) and 11 ⁄ 516 (2%) patients respectively.
Utilization of PERT
Overall, PERT was tried in 363 ⁄ 516 (70%) patients – by
themselves in 263 ⁄ 363 (74%), and in combination with
other medical therapies in 100 ⁄ 363 (26%) patients. A sig-
nificant correlation was seen between PERT usage and
the presence of symptoms (pain and ⁄ or EI) (P < 0.001).
Univariate analyses comparing PERT usage in different
groups are provided in Table 1. There was no difference
in PERT usage based on gender, race, aetiology or pres-
ence of endocrine insufficiency. However, compared to
almost 75% of patients younger than 65 years of age,
PERT had been used in only 50% of patients who were
65 years or older (P = 0.003). PERT usage was also more
frequent in patients with EI and ⁄ or pain.
On multivariate analysis (Table 2), the strongest pre-
dictors for PERT usage were presence of EI and presence
of constant pain. Independent of the presence of pain,
patients with EI were approximately five times more
likely to have used PERT. Similarly, independent of the
presence of EI, patients with intermittent pain were twice
as likely to have used PERT, and those with constant
pain were over three times more likely to have used
PERT, than those with no pain. Patients <65 years of age
were almost three times more likely to have used PERT
compared with patients 65 years or older.
Effectiveness of PERT
In this study, the physicians were not asked to specify
whether PERT was effective for symptoms of maldiges-
tion or pancreatic pain. PERT was considered by physi-
cians as effective in 158 ⁄ 363 (44%) patients. The reported
effectiveness ranged from 28% to 79%. Results of univari-
ate analyses comparing the efficacy of PERT in different
groups are provided in Table 1. Physicians perceived
PERT to be most effective in patients with EI without
pain (19 ⁄ 24, 79%) followed by EI with pain (49 ⁄ 98, 50%),
and least effective in either pain category without EI. In
the univariate analysis, PERT was also perceived as more
effective in patients with endocrine insufficiency, younger
patients and patients without abdominal pain. The effec-
tiveness of PERT appeared to be similar among patients
in the three common aetiological groups.
On multivariate analysis, the only significant predictor
for effectiveness of PERT was the presence of EI (Table 3).
PERT was considered twice as effective in patients with EI
vs. those with no EI. The other significant predictors for
effectiveness of PERT on univariate analyses were no
longer significant in multivariate analyses.
Utilization and efficacy of other medical therapies
In contrast to PERT, other therapies were used infre-
quently in patients with CP: the second most commonly
used modality was AO, in 71 ⁄ 516 (14%), followed by
CPB in 34 ⁄ 516 (7%) and octreotide in 28 ⁄ 516 (5%)
patients. Similar to PERT, the usage of other therapies
correlated with the presence of symptoms (P < 0.01).
Results of univariate analyses comparing the usage and
efficacy of AO, CPB and octreotide in different groups
are provided in Table 4. Although no significant differ-
ences were seen in the proportion of patients in whom
individual therapies were used, largely due to small sam-
ple sizes, interesting trends were noted. Not surprisingly,
CPB was used more often in patients who reported con-
stant or severe pain, and in patients with alcohol or idio-
pathic aetiologies, and was used less often in those aged
more than 65 years. Octreotide was tried more often in
patients who reported pain, had no EI and had obstruc-
tive or idiopathic aetiologies.
As indicated in Table 4, the efficacy of AO was gener-
ally considered poor, with the best efficacy of 25% in
patients who were young, and in those who had obstruc-
tive and idiopathic rather than alcoholic aetiologies
(P = 0.03). When used, the efficacy of CPB and octreo-
tide was highly variable, ranging from 20% to 100%.
Subgroup analyses
The results of subgroup analyses by gender were gener-
ally similar to the overall analyses (data not shown).
DISCUSSION
The present study reports on the use and perceived effec-
tiveness of medical therapies that are used for treating
pain in CP by targeting possible pain-generating mecha-
nisms. A number of observations from this study con-
firm and strengthen previous observations, and add
perspective to a complex condition. The primary finding
was that PERT were widely used, whereas the use of AO,
CPB and octreotide in clinical practice in the US is rela-
tively infrequent. In this group, more than half of the
patients treated did not have EI. As expected, PERT were
very helpful in treating patients with EI, although physi-
cians still considered it helpful in one-third of subjects
F. Burton et al.
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Table 1 | Univariate associations for the use and efficacy of PERT in chronic pancreatitis patients in the North Ameri-









Male 52 68 0.29 42 0.44
Female 49 73 46
Age
<35 18 77 0.003 39 0.36
35–44 21 79 38
45–64 44 70 47
65+ 16 52 50
Race
White 85 69 0.27 44 0.63
Other 15 76 41
Aetiology
Alcohol 44 70 0.68 47 0.04
Obstructive 9 78 49
Idiopathic 29 69 47
Other 19 71 28
Pain presence
Yes 77 74 0.002 40 0.015
No 23 59 56
Pain pattern
No pain 23 59 <0.0001 56 0.05
Constant 43 81 40
Intermittent 34 65 41
Pain severity
No pain 23 59 0.005 56 0.04
Mild-moderate 17 69 36
Severe 60 75 42
Exocrine insufficiency (n = 480)
Yes 29 88 <0.0001 56 0.0005
No 71 61 36
Patient group (n = 480)
Pain (+), EI ()) 57 66 <0.001 36 <0.001
Pain (+), EI (+) 23 90 50
Pain ()), EI (+) 6 80 79
Pain ()), EI ()) 14 39 35
Endocrine insufficiency (n = 480)
Yes 26 69 0.80 55 0.008
No 74 70 39
Values in bold denote statistically significant P-values.
EI, exocrine insufficiency; PERT, pancreatic enzyme replacement therapy; ‘% in sample’, proportion of overall study sample (i.e.
patients in whom any medical, endoscopic or surgical treatment modality was utilized, n = 516); ‘% enzymes tried’, proportion of
individual subgroup in whom PERT was tried; ‘% enzymes effective’, among patients receiving PERT, proportion in whom they
were considered to be effective.
* P-value – differences in proportion for utilization of enzymes.
 P-value – differences in proportion for effectiveness of enzymes.
Medical therapies in chronic pancreatitis
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with pain, but without EI. AO appeared to be most use-
ful in patients with non-alcohol-related CP, although it
was ranked as the least helpful of the three medications
under all conditions. Octreotide appeared to be most
helpful treatment in patients with alcohol-related CP.
The present study has major strengths and limitations.
The strengths include its multi-centre approach, the use
of pancreatic experts for phenotyping and the use of best
available tools for this study. The primary limitation is
that this was a single visit analysis of a large, cross-sec-
tional cohort of CP patients evaluated at expert centres
in the US, and therefore reflects the therapies tried until
the time of enrolment and may not fully reflect the prac-
tice of the expert consultant. Secondly, the indication(s)
for prescribing medical therapies were unknown. Third,
the specific dosage or formulation of PERT (enteric- or
non-enteric coated) or AO was not evaluated. Fourth, as
in all observational studies, it was not possible to stan-
dardize treatment dose or duration, the measures of
effect, and ⁄ or end point(s) and there were no placebo
controls limiting our ability to address potential physi-
cian bias. There may also be a referral bias of patients
from the community to referral centres who failed stan-
dard therapies. The study was also limited by small num-
ber of patients in whom AO, octreotide and CPB were
attempted. Furthermore, comparison of subjects by pres-
ence and type of pain was based on the time of enrol-
ment, and not necessarily at the time of attempted
treatment. These factors limit the analysis of the data set
to observations of the use of medical therapies in the
community, and their perceived usefulness under typical
practice conditions. However, it provides very important
information about current use of these therapies in the
US, and may be very useful in determining feasibility
and power in future prospective studies.
Pancreatic enzyme supplements
Pancreatic enzyme replacement therapy is used both for
treating maldigestion and for treating pain. There is no
controversy as to whether PERT is both useful and med-
ically necessary in the treatment of patients with EI (e.g.
cystic fibrosis, advanced CP and pancreatic resection).
Defining the physiological threshold for pancreatic insuf-
ficiency is complicated by poorly defined or inconsistent
endpoints (e.g. biochemical measures of protein nutri-
tion,20 faecal elastase concentrations21, 22 and steator-
rhea23), by the varying nutritional needs and meal sizes
of individual patients. Furthermore, the threshold for
prescribing PERT by the managing physician is also vari-
able, often depending on the signs and symptoms of
maldigestion (e.g. unexplained weight loss, bloating,
abdominal cramping, diarrhoea, steatorrhoea) and
patient complaints rather than relying on measures of
pancreatic exocrine function and nutritional needs. The
findings of the present study strongly support the role of
PERT in the treatment of patients with EI with and
without pain.
Isaksson and Ihse24 reported a double-blinded, pla-
cebo-controlled, randomized trial of non-enteric-coated
PERT in patients with CP for the treatment of pain.
Table 3 | Independent predictors of PERT efficacy in
chronic pancreatitis patients in the North American






Gender: male vs. female 0.83 0.53–1.29
Age
<35 vs. 35–44 1.16 0.59–2.31
45–64 vs. 35–44 1.51 0.85–2.69
65+ vs. 35–44 1.67 0.76–3.66
Exocrine insufficiency 2.16 1.36–3.42
Gender and age were forced into the model. Other variables
entered into the model were frequency of pain, severity of
pain, endocrine insufficiency and race.
PERT, pancreatic enzyme replacement therapy
Table 2 | Independent predictors of PERT use in chronic
pancreatitis patients in the North American Pancreatitis






Gender: male vs. female 0.86 0.56–1.32
Age
<35 vs. 35–44 1.03 0.50–2.09
45–64 vs. 35–44 0.62 0.34 –1.10
65+ vs. 35–44 0.35 0.18–0.71
Pain
Constant vs. no pain 3.42 1.93– 6.04
Intermittent vs. no pain 1.98 1.14–3.45
Exocrine insufficiency 5.14 2.87–9.18
Gender and age were forced into the model. Other variables
entered into the model were severity of pain, endocrine insuffi-
ciency, aetiology and race. Interaction between pain and exo-
crine insufficiency was not significant.
PERT, pancreatic enzyme replacement therapy.
F. Burton et al.
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Fifteen of 19 (79%) patients treated with a pancreatic
enzyme supplement during the 1-week treatment period
had an average pain reduction of 30%.24 Four additional
studies were subsequently published, including one posi-
tive study using non-enteric-coated enzymes25 and three
negative studies using enteric-coated enzymes,26–28 but
the individual, and combined results9 failed to demon-
strate significant benefit over placebo. However, an argu-
ment has been made that this approach is effective in
minimal change, or ‘small duct’ CP, and requires the use
Table 4 | Univariate associations for the use and efficacy of vitamins and antioxidants, coeliac plexus block and octreo-




Vitamins ⁄ antioxidants Coeliac plexus block Octreotide
% Tried % Effective % Tried % Effective % Tried % Effective
Gender
Male 52 16 16 6 40 5 64
Female 48 11 11 8 37 6 43
Age *
<35 18 17 25 6 67 5 20
35–44 21 12 8 9 40 6 57
45–64 44 14 16 7 25 6 77
65+ 16 13 0 2 50 4 0
Race
White 85 14 15 6 39 5 57
Other 15 13 10 8 33 6 40
Aetiology
Alcohol 44 12 4 7 40 4 75
Obstructive 9 16 29 2 100 4 50
Idiopathic 29 17 24 9 36 7 55
Other 19 12 9 4 25 7 29
Pain presence
Yes 77 13 11 8 40 6 56
No 23 15 22 3 25 3 33
Pain pattern
No pain 23 15 22 3 25 3 50
Constant 43 14 13 13 36 7 60
Intermittent 34 13 9 1 100 6 33
Pain severity *
No pain 23 15 22 3 25 3 33
Mild–moderate 17 11 10 5 75 7 33
Severe 60 14 12 8 35 6 63
Exocrine insufficiency (n = 480) *
Yes 29 16 18 9 25 1 54
No 71 12 7 6 47 7 100
Endocrine insufficiency (n = 480)
Yes 26 13 12 8 30 4 60
No 74 13 10 6 46 6 55
‘% in sample’, proportion of overall study sample (i.e. patients in whom any medical, endoscopic or surgical treatment modality
was utilized, n = 516); ‘% tried’, proportion of individual subgroup in whom treatment was tried; ‘% effective’, among patients
who received treatment, proportion in whom it was considered to be effective.
* P < 0.05.
Medical therapies in chronic pancreatitis
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of high potency, uncoated pancreatic enzymes,12 prefera-
bly with acid suppression.29 After reviewing this litera-
ture, Brown et al.9 concluded that what is needed is an
adequately powered study, with emphasis on minimizing
patient and drug heterogeneity and use of enzyme prepa-
rations that provide adequate concentrations of proteases
in the duodenum. The present study does suggest that
many physicians treating CP patients with pain, but
without EI, have used PERT. There appears to be per-
ceived usefulness in treating patients without EI, and this
effect appeared to be similar in patients with (36%) and
without pain (35%). Due to the cross-sectional design, it
is unclear if PERT were used in the latter group to treat
symptoms of maldigestion or pain without clinically
obvious EI or whether this apparent improvement in
symptoms reflects of placebo effect. However, in patients
with pain, PERT was judged to be more useful in
patients with EI (50%) than in those with pain alone
(36%). Thus, PERT appear to have an important role in
the treatment of CP patients, but the effect on pain is
smaller than on EI alone (79%). The possibility that
PERT are effective in a special subset of patients with
‘small duct’ disease,12 or hereditary pancreatitis30 has not
been excluded. Whether PERT is helpful in patients with
pain alone needs to be addressed in prospective trials
with appropriate study design and follow-up.
Vitamins ⁄antioxidants
A nonsignificant result for perceived effectiveness between
aetiologies overall could be due to small sample sizes
(resulting in a type II error), which limits our ability to
draw definite conclusions. However, when comparing
effectiveness of AO in subgroup analyses, physicians did
report a significantly higher effectiveness for AO in patients
with idiopathic and obstructive aetiologies (P = 0.03) when
compared with alcohol-related CP (Table 4).
While early trials on the use of a single AO were dis-
appointing,13 two recent studies suggest that combination
AO may be useful for the treatment of pain in a subset
of patients with CP.14, 31 In the study by Kirk et al.,31 36
patients with CP were recruited, but only 23 patients
completed the study. Data from pain diaries were disre-
garded and the results represented the data from the SF-
36 questionnaires completed by patients who completed
the study. This study showed that a combination AO
improved abdominal pain and several aspects of quality
of life in patients with CP. It is hard to compare the
results of this study to ours because the aetiology of CP
was not specified.31 On the other hand, a more recent
study from India evaluated AO in 127 patients, most of
whom had idiopathic CP.14 It showed that combination
AO (much higher doses compared with those in the pre-
vious study) was effective in reducing the number of
painful days per month, requirement of analgesics, need
for hospitalization and the percentage of patients who
became pain-free. However, significant postrandomiza-
tion dropouts and other methodological issues limit the
strength of the conclusion of this trial.32 Our study sug-
gests that providers considered AO to be more helpful in
obstructive and idiopathic CP than alcoholic CP, but the
25% effectiveness rate is similar to placebo in many ran-
domized trials of abdominal pain.
Coeliac plexus block
The utility of CPB for pancreatic pain was first recog-
nized in patients with pancreatic cancer.33 Wiersema and
Wiersema34 first demonstrated that CPB could be done
using EUS, and Gress et al.35 went on to demonstrate
that it could provide significant improvement in pain
scores with reduction in pain medication usage in half of
treated patients. In the current study, CPB was used in
6% of men and 8% of women. Although the numbers
are small, it appears that this therapy was used more
often in patients with constant pain, but was more effec-
tive in those with mild-moderate pain.
Octreotide
Octreotide has been evaluated for pain in CP mainly
when other medical therapies have failed. Octreotide is a
potent inhibitor of pancreatic exocrine secretion36 and
may work through several mechanisms,37 including a
direct effect38 and inhibiting neural stimulation.39 It may
have anti-inflammatory properties40 and reduce sphincter
of Oddi pressure.41
A few small studies published in abstract form42–44or as
full manuscripts11, 45, 46 have reported on the efficacy of
octerotide in painful CP. In 1993, in a placebo-controlled,
double-blind, dose-finding study, octreotide 200 lg given
three times a day was reported to be more effective than
placebo in reducing pain.43 The benefit was more promi-
nent in the subgroup of patients with constant daily
pain.43 An open label extension published in 199444sug-
gested that by 6 weeks, 50% of patients still had continued
pain relief for 6 weeks.44 In contrast, a small German
study showed no difference in pain control or analgesic
use during a short-term (3 days) double-blind cross-over
study.11 In 2009, a study from the US compared long-act-
ing octreotide with short-acting octreotide in the treat-
ment of painful CP in a small open-label, unblinded pilot
study.46 Lieb et al.46 reported that in seven patients with
F. Burton et al.
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severe CP and constant daily pain, once-monthly depo-
octreotide (Octreotide LAR; Novartis, East Hanover, NJ,
USA), 60 mg intramuscular injection, may be a useful sub-
stitute for short-acting octreotide that must be injected
three times a day. We found that octreotide was seldom
used in the clinical practice of gastroenterologists at the
NAPS2 sites, but was judged by the provider to be of some
benefit in a few patients.
CONCLUSION
The current report provides a cross-sectional perspective
on the current use of non-analgesic medical therapies in
CP in the US. The major finding is that PERT is the
most commonly used treatment in this class, and pro-
vides a significant perceived benefit not only for EI but
also for pain in a subset of patients, especially those with
EI. The second finding is that AO do appear to be useful
in patients with non-alcohol-related CP, but not in alco-
holic CP. Thirdly, CPB and octreotide treatment may be
useful in a small subset of patients, but the limited use
of these therapies limits any further interpretations.
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APPENDIX
The following physicians and centres also contributed patients to the NAPS2 study: Mary E. Money, Washington
County Hospital, Hagerstown, MD; Robert H. Hawes, MD; Peter B. Cotton, MD, Digestive Disease Center, Medical
University of South Carolina, Charleston, SC; James DiSario, MD, Department of Medicine, University of Utah
Health Science Center, Salt Lake City, UT; Simon K. Lo, MD, Department of Medicine, Cedars-Sinai Medical Center,
University of California, Los Angeles; Mark T. DeMeo, MD, Department of Medicine, Rush University Medical Cen-
ter, Chicago, IL; William M. Steinberg MD, Washington Hospital Center, Washington, DC; Michael L. Kochman,
MD, Department of Medicine, University of Pennsylvania, Philadelphia, PA; Babak Etemad, MD, Department of Gas-
troenterology and Hepatology, Ochsner Medical Center, New Orleans, LA.
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